Literature DB >> 9740606

Reproducibility and clinical value of the trough-to-peak ratio of the antihypertensive effect: evidence from the sample study.

S Omboni1, R Fogari, P Palatini, A Rappelli, G Mancia.   

Abstract

The objectives of our study were to assess the reproducibility of the trough-to-peak ratio (T/P) and to see whether a high T/P is accompanied by more organ protection or vice versa. The study included 175 (mean+/-SD age, 51+/-9 years) subjects with mild-moderate essential hypertension who had echocardiographic evidence of left ventricular (LV) hypertrophy taken from the SAMPLE study (Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation), an open-label multicenter study. The study included a 3-week washout pretreatment period, a 12-month treatment period with lisinopril (n=84) or lisinopril plus hydrochlorothiazide (n=91) once daily, and a 4-week placebo follow-up period. Results of 24-hour ambulatory blood pressure monitoring and echocardiographic determination of left ventricular mass index (LVMI) were obtained before and after 3 and 12 months of treatment. T/Ps were computed in each patient by dividing the systolic and diastolic blood pressure changes at trough (changes in the last 2 hours of the monitoring period) by those at peak (average of the 2 adjacent hours with the maximal blood pressure reduction between the 2nd and 8th hour from drug intake) after 3 and 12 months of treatment. Average 24-hour blood pressure was similarly reduced at 3 and 12 months. Trough blood pressure changes at 3 and 12 months were closely correlated, as were the corresponding peak blood pressure changes. However, the 3- and 12-month T/Ps correlated to a lesser degree (r<0.42). Furthermore, the reduction of LVMI induced by treatment was similarly correlated with the treatment-induced reduction in 24-hour average, trough, and peak blood pressures but not with the T/Ps. This was also evident when the contribution to LV hypertrophy regression by 24-hour blood pressure changes and T/Ps was assessed in a multivariate regression analysis. In patients with a T/P >/=0.5 or <0.5, the regression of LVMI was similar. In conclusion, peak and trough blood pressure changes are reproducible and predict the regression of LVMI induced by treatment as well as average 24-hour blood pressure. T/Ps are less reproducible, and their value does not predict regression of organ damage by antihypertensive treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740606     DOI: 10.1161/01.hyp.32.3.424

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

Review 1.  Clinical significance of home blood pressure and its possible practical application.

Authors:  Yutaka Imai
Journal:  Clin Exp Nephrol       Date:  2013-07-03       Impact factor: 2.801

Review 2.  Ambulatory blood pressure monitoring: from old concepts to novel insights.

Authors:  Mehmet Kanbay; Kultigin Turkmen; Tevfik Ecder; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2011-07-06       Impact factor: 2.370

3.  Italian society of hypertension guidelines for conventional and automated blood pressure measurement in the office, at home and over 24 hours.

Authors:  Gianfranco Parati; Stefano Omboni; Paolo Palatini; Damiano Rizzoni; Grzegorz Bilo; Mariaconsuelo Valentini; Enrico Agabiti Rosei; Giuseppe Mancia
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-22

4.  Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR.

Authors:  Dénes Páll; Ildikó Szántó; Zoltán Szabó
Journal:  Clin Drug Investig       Date:  2014-10       Impact factor: 2.859

5.  Ambulatory blood pressure in hypertensive patients with left ventricular hypertrophy: efficacy of first-line combination perindopril/indapamide therapy.

Authors:  Roland Asmar; Juan Garcia-Puig; Philippe Gosse; Yuri A Karpov; Peter Wilhem De Leeuws; Dieter Magometschniggs; Lajos Matos; Roland Schmieder
Journal:  Vasc Health Risk Manag       Date:  2007
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.